Buscar
01/03/2025
Cardiac denervation and morpho-functional changes, two sides of the same coin in wild-type transthyretin amyloid cardiomyopathy?
Flotats, A. Cardiac denervation and morpho-functional changes, two sides of the same coin in wild-type transthyretin amyloid cardiomyopathy?. JOURNAL OF NUCLEAR CARDIOLOGY. 2025; 45DOI:10.1016/j.nuclcard.2025.102145. PMID:39870299. IF:2.700(Q2/4D).
01/03/2025
Designing an integrated care pathway for spondyloarthritis: A Lean Thinking approach
Lobo-Prat, D, Sainz, L, Laiz, A, De Dios, A, Fontcuberta, L, Fernández, S, Masip, M, Riera, P, Pages-Puigdemont, N, Ros, S, Gomis-Pastor, M, Corominas, H. Designing an integrated care pathway for spondyloarthritis: A Lean Thinking approach. JOURNAL OF EVALUATION IN CLINICAL PRACTICE. 2025; 31(2)DOI:10.1111/jep.14132. PMID:39253893. IF:2.100(Q2/3D).
01/03/2025
Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment
Redondo, S, Costa, M, Moreno-Martinez, ME, Arguello-Tomas, M, Riba, M, Aso, O, Iranzo, E, Esquirol, A, Sierra, J, Briones, J, Martino, R, Zapico, E, Garcia-Cadenas, I. Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment. EUROPEAN JOURNAL OF HAEMATOLOGY. 2025; 114(3)DOI:10.1111/ejh.14349. PMID:39545520. IF:2.300(Q2/5D).
01/03/2025
Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study
Puig L., Daudén E., Cuervas-Mons M., Novella C., Guisado C.. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39DOI:10.1111/jdv.19403. PMID:37567861. IF:8.000(Q1/1D).
01/03/2025
The impact on pain and mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey
Kokolakis, G, Guillem, P, Vilarrasa, E, Alarcon, I, Go, M, Newbold, G, Mamareli, A, Richardson, C, McGrath, B, Kirby, JS. The impact on pain and mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).
01/03/2025
Lymphedema in hidradenitis suppurativa: A multicenter case series
Garbayo-Salmons, P, Vilarrasa, E, Haselgruber, S, Gamissans, M, Ciudad, C, Martorell, A, Aguayo-Ortiz, RS, Romani, J, Fornons-Servent, R, Molina-Leyva, A. Lymphedema in hidradenitis suppurativa: A multicenter case series. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).
01/03/2025
Major predictors of remission in hidradenitis suppurativa: An 8-year survival study with adalimumab
Vilarrasa, E, Salmons, PG, Bassas-Vila, J, Mora, V, Fuertes, I, Luque, M, Fornons-Servent, R, Martin, G, Aguayo-Ortiz, RS, Ceravalls, J, Mollet, J, Gómez, A, Masferrer, E, Corral, O, Matas, C, Romaní, J. Major predictors of remission in hidradenitis suppurativa: An 8-year survival study with adalimumab. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).
01/03/2025
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Silverberg, JI, Bieber, T, Paller, AS, Beck, L, Kamata, M, Puig, L, Wiseman, M, Ezzedine, K, Irvine, AD, Foley, P, Del Rosso, J, Gold, LS, Johansson, E, Dossenbach, M, Gallo, G, Akmaz, B, Casillas, M, Karlsson, A, Curteis, T, Chovatiya, R. Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy. Dermatology and Therapy. 2025; 15(3)DOI:10.1007/s13555-025-01357-7. PMID:39953372. IF:4.200(Q1/1D).